Overview

New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to Severe Asthma

Status:
Completed

Trial end date:
2008-04-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy and safety of the fixed combination asthma drug FlutiForm with its two components administered alone, fluticasone propionate and formoterol fumarate, and with placebo in adult and adolescent patients with moderate to severe asthma.

Phase:

Phase 3

Details

Lead Sponsor:

SkyePharma AG

Treatments:

Fluticasone
Formoterol Fumarate
Xhance